Caffeine citrate


On 11 April 2014, orphan designation (EU/3/14/1261) was granted by the European Commission to Viridian Pharma Ltd, United Kingdom, for caffeine citrate for the prevention of bronchopulmonary dysplasia.

Key facts

Active substance
Caffeine citrate
Intented use
Prevention of bronchopulmonary dysplasia
Date of designation
Orphan designation status
EU designation number

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Viridian Pharma Ltd
Yew Tree House, Hendrew Lane
Llandevaud, Newport
Gwen, NP18 2AB
United Kingdom
Tel. +44 (0)163 3400 335
Fax +44 (0)163 3400 335

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

Related content

How useful was this page?

Add your rating